Article citationsMore>>

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., et al. (2021) Camrelizumab Plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (Camel): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314.
https://doi.org/10.1016/s2213-2600(20)30365-9

has been cited by the following article:

• TITLE: Efficacy and Safety of Primary Radiotherapy in Combination with EGFR-TKIs for Non-Small Cell Lung Cancer Harboring EGFR Mutation

  AUTHORS: Dongxu Ao, Meng Wang, Jinyuan Xie, Yang Zhang, Xinran Zhang, Ya Shu, Chenshi Lin, Qingqing Ye

  KEYWORDS: Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Radiotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.9, September 19, 2024

  ABSTRACT: Objective: To evaluate the efficacy and safety of EGFR-TKI with the radiotherapy in EGFR mutant metastatic NSCLC. Methods: Retrospective analysis of 72 patients with stage IV lung cancer with EGFR-sensitive mutation. Patients in the A group were treated with the first-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) combined with radiotherapy for primary tumors (34 cases). The B group was treated with the first-generation EGFR-TKI alone until the disease progressed (38 cases). PFS, OS, pulmonary infection and hematological toxicity during treatment were commented in both groups. Results: The objective remission rate was 47.1% (16/34) in the A group and 21.1% (8/38) in the B group. There was a significant difference between the two groups. There was no significant difference in hematological toxicity between the A group and the B group. There were 10 patients (29.4%) with degree II pulmonary infection in the A group and 3 patients (7.9%) in the B group. The difference between the two groups was statistically significant, suggesting that the incidence of pneumonia in the A group was higher than that in the B group. The median PFS (Progression-Free Survival)) and OS (Overall Survival) of the A group were significantly longer than those of the B group (16.5 months vs 9 months) and the median OS (36 months vs 19 months). The PFS and OS in the A group were significantly longer than those in the B group. Conclusion: EGFR-TKI combined with primary radiotherapy can significantly prolong the drug resistance time of EGFR mutant metastatic NSCLC.